2024
Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US
Kerekes D, Frey A, Prsic E, Tran T, Clune J, Sznol M, Kluger H, Forman H, Becher R, Olino K, Khan S. Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US. JAMA Oncology 2024, 10: 342-351. PMID: 38175659, PMCID: PMC10767643, DOI: 10.1001/jamaoncol.2023.6025.Peer-Reviewed Original ResearchNon-small cell lung cancerEnd of lifeMonth of deathImmunotherapy initiationCohort studyMAIN OUTCOMEStage IV non-small cell lung cancerCharlson-Deyo comorbidity indexHigh metastatic burdenInitiation of immunotherapyNational prescribing patternsRisk-adjusted patientsImmune checkpoint inhibitorsRetrospective cohort studyStage IV melanomaPercentage of patientsHigh-volume centersLocation of metastasesLow-volume centersOdds of deathCell lung cancerNational Clinical DatabaseLow-volume facilitiesDrug Administration approvalCheckpoint inhibitorsImmunotherapy utilization in stage IIIA melanoma: less may be more
Frey A, Kerekes D, Khan S, Tran T, Kluger H, Clune J, Ariyan S, Sznol M, Ishizuka J, Olino K. Immunotherapy utilization in stage IIIA melanoma: less may be more. Frontiers In Oncology 2024, 14: 1336441. PMID: 38380358, PMCID: PMC10876869, DOI: 10.3389/fonc.2024.1336441.Peer-Reviewed Original ResearchStage IIIA melanomaHigh-volume centersRisk-adjusted survivalLow-volume centersImmunotherapy utilizationAdjuvant immunotherapyStage IIIATreatment of stage III melanomaAcademic centersMultivariable Cox proportional hazards regressionStage III melanomaNational Cancer DatabaseStage III diseaseFactors associated with receiptCox proportional hazards regressionCompare patient outcomesProportional hazards regressionIII melanomaImmunotherapy receiptReceiving immunotherapyIII diseaseImmunotherapy agentsOverall survivalSurvival benefitAdjuvant treatment
2019
Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival
Uhlig J, Sellers CM, Khan SA, Cha C, Kim HS. Hepatocellular carcinoma: Impact of academic setting and hospital volume on patient survival. Surgical Oncology 2019, 31: 111-118. PMID: 31654956, DOI: 10.1016/j.suronc.2019.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAcademic Medical CentersAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, HepatocellularCombined Modality TherapyDatabases, FactualFemaleFollow-Up StudiesHepatectomyHospitals, High-VolumeHospitals, Low-VolumeHumansLiver NeoplasmsLiver TransplantationMaleMiddle AgedPractice Patterns, Physicians'PrognosisRetrospective StudiesSurvival RateConceptsOverall survivalHepatocellular carcinomaAcademic centersHospital volumePatient survivalInterventional oncologyYoung African American patientsHigh-volume academic centersMultivariable Cox regressionFirst-line treatmentLow-volume centersLonger patient survivalAfrican American patientsHCC treatment modalitiesNon-academic centersLiver transplantMultivariable adjustmentPatient demographicsSurgical resectionLine treatmentCox regressionPotential confoundersVolume centersTreatment modalitiesAmerican patients